Telemedizin ist der Einsatz von Telekommunikation und Informatik, um medizinische Dienstleistungen zu erbringen oder zu unterstützen, wenn die Teilnehmer räumlich getrennt sind. Die einzelnen telemedizinischen Anwendungen sind im Vordringen begriffen. Telemedizin ist allerdings kein eigenes Fachgebiet, sondern eine Methode, herkömmliche medizinische Maßnahmen zu unterstützen und zu verbessern. Da die Teilnehmer telemedizinischer Anwendungen nicht am selben Ort und zur selben Zeit agieren müssen, ist Telemedizin prädestiniert für die Überwindung der Sektorierung des Gesundheitssystems. Telemedizin kann insbesondere Rationalisierungsreserven mobilisieren und medizinische Dienstleistungen effektiver und effizienter gestalten. Ungeachtet dessen gibt es fünf Problemfelder, die beobachtet und weiter entwickelt werden müssen, um Telemedizin auch für die Zukunft möglich zu machen: Die unterschiedlichen Kommunikationsstandards müssen harmonisiert werden, damit der Datenfluß zwischen den Teilnehmer optimiert werden kann. Krankenkassen und Leistungserbringer müssen gemeinsam eine solide Basis für die Finanzierung derjenigen telemedizinischen Dienstleistungen etablieren, die dem Stand der wissenschaftlichen Erkenntnis entsprechen. Telemedizin mit Auslandsbeteiligung zieht in der Regel haftungsrechtliche Kollisionen nach sich, die von den Teilnehmern durch eine Rechtswahl- und eine Gerichsstandsvereinbarung vermieden werden können. Die sozialrechtlichen Möglichkeiten, insbesondere solche, Praxisnetze zu bilden, müssen noch in Einklang mit den berufsrechtlichen Vorgaben gebracht werden, da diese einer überörtlichen Leistungserbringergemeinschaft und einer entsprechenden Information des Patienten zum Teil noch im Weg stehen.Die durch die Telemedizin neu entstehenden Möglichkeiten der Kommunikation müssen durch zusätzliche Maßnahmen für Datenschutz und Datensicherheit flankiert werden. Insbesondere bei Datenübertragungen ins Ausland sollten sich die Teilnehmer durch eine gesonderte Einwilligung des Patienten in diesen Datenfluß absichern. / Telemedicine is the use of information and telecommunication technologies to provide and support health care when distance separates the participants. The single uses of telemedicine are growing in quality and quantity. Telemedicine, however, is not a medical field of its own, but a tool that can be used in most fields of medicine to enhance and support communication procedures. Since the participants must not act at the same time and at the same venue, telemedicine is bound to overcome the sectoral boundaries in a health system, which is separated in an outpatient and an inpatient world. Telemedicine can help to mobilise the health systems rationalisation potential and make procedures more effective and more efficient. There still are five tasks that have to be observed and to be solved, to make telemedicine possible in the future: Harmonisation of communicational standards must progress to optimise communication between the participants. Health insurance funds and medical persons must cooperate to insure a solid basis of financing for telemedicinal procedures that are state of the art. Participants of cross-border telemedicine must be aware of colliding laws and are well advised to agree upon the law to be applied and the court in charge. The professional law for doctors in Germany must be reconciled with the managed care concepts of practice networks that are legally permissible in terms of social law. Data protection and data security must be ensured under the new conditions of telemedicine. Especially cross-border data flow should be based on the informed consent of the patient involved

Submitted by ROGERIO BAPTISTA TEIXEIRA FERNANDES (rogeriobteixeira@yahoo.com.br) on 2016-04-25T21:50:10Z No. of bitstreams: 1 EBAPE Dissertação MAP Turma Intensiva Rogerio Fernandes PDF.pdf: 709868 bytes, checksum: 58f8d5750c16cdab6971c0c2bc1d8cad (MD5) / Approved for entry into archive by ÁUREA CORRÊA DA FONSECA CORRÊA DA FONSECA (aurea.fonseca@fgv.br) on 2016-04-29T15:34:19Z (GMT) No. of bitstreams: 1 EBAPE Dissertação MAP Turma Intensiva Rogerio Fernandes PDF.pdf: 709868 bytes, checksum: 58f8d5750c16cdab6971c0c2bc1d8cad (MD5) / Approved for entry into archive by Marcia Bacha (marcia.bacha@fgv.br) on 2016-05-09T14:48:55Z (GMT) No. of bitstreams: 1 EBAPE Dissertação MAP Turma Intensiva Rogerio Fernandes PDF.pdf: 709868 bytes, checksum: 58f8d5750c16cdab6971c0c2bc1d8cad (MD5) / Made available in DSpace on 2016-05-09T14:49:08Z (GMT). No. of bitstreams: 1 EBAPE Dissertação MAP Turma Intensiva Rogerio Fernandes PDF.pdf: 709868 bytes, checksum: 58f8d5750c16cdab6971c0c2bc1d8cad (MD5) Previous issue date: 2015-12-21 / The reimbursement to the Unified Health System (SUS), created by Law No. 9.656 of 1998, showed impressive results in the period 2011-2014, compared to the period 2007-2011. This exploratory study analyzes the reimbursement to the SUS, its origin, legal support, juridical basis, organization, functioning, operating performance and effectiveness, focusing on results achieved in the period 2011-2014. In order to accomplish, the author relied on previous studies, official documents and reports, legislation, judgments of the Court of Audit and lawsuits filed before the Supreme Court. The analysis indicates that the results achieved in the last four years are promising, reflecting a favorable scenario for the consolidation of reimbursement to SUS as an important regulatory instrument for the supplementary health sector. / O ressarcimento ao Sistema Único de Saúde (SUS), criado pela Lei n. 9.656, de 1998, apresentou resultados expressivos no período 2011-2014, em contraposição ao período 2007-2010. O presente estudo, de caráter exploratório, buscou analisar o ressarcimento ao SUS, sua origem, base legal, fundamentação jurídica, organização, funcionamento, desempenho operacional e efetividade, com foco nos resultados alcançados no período 2011-2014. Para isso, o autor apoiou-se em estudos anteriores, em documentos e relatórios oficiais, na legislação em vigor, nos acórdãos do Tribunal de Contas da União e nas ações ajuizadas perante o Supremo Tribunal Federal. As análises efetuadas indicam que os resultados alcançados nos últimos quatro anos são promissores, refletindo um cenário favorável à consolidação do ressarcimento ao SUS como um importante instrumento de regulação para o setor de saúde suplementar.

L'infertilité affecte 11-15 % des Canadiennes et 8-20 % des couples ont de la difficulté à concevoir spontanément. Par conséquent, le recours à la procréation médicalement assistée (PMA) ne cesse d'augmenter, cependant la controverse demeure quant à ses risques sur la santé maternelle et celle des enfants. La PMA comprend les techniques de procréation assistée (TRA) (fécondation in vitro [FIV], insémination intra-utérine [IIU]) et les stimulateurs ovariens (SO), avec plus de 5 millions d'enfants issu d’une FIV au monde. La PMA a précédemment été associée à un risque accru d’issues adverses de grossesse incluant l’hypertension gestationnelle, les saignements utérins ainsi que les issues adverses affectant la santé de l’enfant, notamment les grossesses multiples, la prématurité, et le faible poids à la naissance sur lesquelles nous allons nous concentrer dans cette thèse de doctorat. Entre 05/08/2010-15/11/2015, le Québec fut la 1ère province Canadienne à financer un programme de remboursement universel pour la PMA, visant à augmenter le taux de natalité au Québec et réduire les grossesses multiples et leurs dépenses de santé associées en implémentant le transfert d'embryon unique. Le programme a été interrompu en 2015 dû aux dépenses de santé plus élevées que prévu. Nous avons identifié plusieurs lacunes de connaissances, que nous avons cherché à combler dans ce programme doctoral. Premièrement, aucun registre n’a été mis en place pour évaluer l'impact du programme sur les mères et les enfants. Deuxièmement, les études se concentrent sur les TRA ou combinent toutes les méthodes non-FIV, ce qui a des implications cliniques limitées. Les SO sont sous-analysées mais ont des implications cliniques importantes car ils constituent un traitement de première ligne pour l'infertilité. Enfin, les grossesses singleton sont moins évaluées alors qu’il est devenu évident qu'elles comportent des risques périnataux cliniquement importants. Cette thèse de doctorat est composée d'une revue de la littérature publiée et de trois études épidémiologiques effectuées dans la Cohorte des Grossesses du Québec (CQG). L'étude 1 quantifie les variations des tendances trimestrielles des issues obstétricales et périnatales 5 ans avant et pendant le programme québécois, et quantifie le risque de multiplicité associé au programme et à la PMA dans l’ensemble et par sous-types (SO seuls, TRA seuls, SO/TRA combinés) pendant ses années actives. Nous avons aussi étudié le rôle des grossesses multiples comme modificateur d'effet dans l'association entre la PMA et la prématurité. Entre 2005-2015, nous avons observé une augmentation de la prévalence de multiplicité par un facteur de 10. Les grossesses multiples ont augmenté significativement pendant le programme (rapport de cotes ajusté [RCa] 6,09, intervalle de confiance à 95 % [IC95%] 5,23-7,09) par rapport aux 5 ans avant. La PMA a significativement augmenté le risque de multiplicité (RCa 4,65, IC95% 3,84-5,62) par rapport à la conception spontanée. Les SO seuls augmentaient le plus le risque de multiplicité (RCa 6,28, IC95 % 4,56-8,64) par rapport à la conception spontanée. L’étude 2 quantifie le risque de prématurité associé à la PMA dans l'ensemble et par sous-type parmi les grossesses singleton survenues pendant le programme et dans une cohorte restreinte de grossesses PMA pour évaluer l'impact d’un biais d'indication (l’infertilité ou la sous-fertilité) potentiel. La PMA dans l’ensemble (RCa 1,46, IC95 % 1,25-1,72) et par sous-types : OS seul (RCa 1,47, IC95% 1,04-2,07), TRA seul (RCa 1,76, IC95% 1,01-3,06) et SO/TRA combinés (RCa 1,43, IC95% 1,19-1,73) étaient associées à un risque accru de prématurité par rapport à la conception spontanée. Enfin, l’étude 3 quantifie le risque de naitre petit/très petit pour l'âge gestationnel associé à la PMA dans l’ensemble et par sous-types. Connaissant l'association PMA/prématurité, nous avons aussi évalué le rôle de la prématurité comme modificateur d'effet dans l'association entre PMA et le fait de naitre petit ou très petit pour l'âge gestationnel. Bien qu'aucune association n'ait été observée entre la PMA et le fait de naitre petit ou très petit pour l'âge gestationnel, la PMA était associée à un risque accru de naitre petit ou très petit pour l'âge gestationnel (RCa 1,69, IC95 % 1,08-2,66) chez les prématurés spécifiquement. Nos résultats démontrent une augmentation significative des grossesses multiples pendant le programme, au-delà des seuils visés. Les SO seuls augmentent particulièrement les grossesses multiples, une technique de PMA ne pouvant être contrôlée par le transfert d’embryon unique. La PMA augmente le risque de prématurité, en particulier chez les singletons. Nos résultats confirment en outre qu’elle augmente également le risque de naitre petit pour l’âge gestationnel, en particulier chez singletons prématurés. / Infertility affects 11-15% of Canadian women, while 8-20% of couples report having difficulties conceiving spontaneously. As such, the use of medically assisted reproduction (MAR) has steadily increased, however controversy remains with regards to its risks on the health of mothers and children. MAR includes assisted reproductive technology (ART) (i.e. in vitro fertilization [IVF], intrauterine insemination [IUI]) and ovarian stimulators (OS), with over 5 million children born through IVF alone worldwide. MARs have previously been associated with an increased risk of adverse pregnancy outcomes including gestational hypertension, uterine bleeding as well as adverse child health outcomes including multiplicity, prematurity, and low birth weight. Perinatal outcomes will be the focus in this doctoral thesis. Between 05/08/2010-15/11/2015, Quebec was the first Canadian province to fund a universal MAR reimbursement program, which aimed to reduce multiplicity and associated health expenditures with the practice of single embryo transfers in the context of IVF and increase Quebec’s birth rate. The program was halted in 2015 following a higher than expected healthcare expenditure. We identified several knowledge gaps, which we have aimed to fill through this doctoral program. First, no database exists to assess the impact of Quebec’s universal MAR program on mothers and children. Second, evidence focuses on ART or combine all non-IVF (e.g. OS) methods together, which has limited clinical implications. OS are under analysed but carry clinical implications as they are a first line therapy for infertility. Lastly, singleton pregnancies are not always evaluated when it has become evident that they carry clinically relevant perinatal risks. This doctoral thesis is composed of a published literature review as well as three epidemiological studies conducted within the Quebec Pregnancy Cohort (QPC). Study 1 aimed to quantify the changes in quarterly trends of obstetrical and perinatal outcomes 5 years before and during the universal program in Quebec through an interrupted time series analysis, as well as quantify the risk of multiplicity in association with the program itself and MAR conceptions specifically during the active program years. In this first study we also aimed to evaluate the role of multiplicity as an effect modifier in the association between MAR conception and prematurity. Between 2005-2015, we observed a 10-fold increase in multiplicity. Multiplicity increased by 6-fold during the program (adjusted odds ratio [aOR] 6.09, 95% confidence interval [CI] 5.23-7.09) compared to 5 years prior. MAR significantly increased the risk of multiplicity by 4.7-fold (aOR 4.65, 95%CI 3.84-5.62) compared to spontaneous conception. OS alone increased the risk of multiplicity the most (aOR 6.28, 95%CI 4.56-8.64) compared to spontaneous conception. In Study 2, we quantified the risk of prematurity associated with MAR conceptions overall and by subtype (eg. OS alone, ART alone, OS/ART combined) among singleton pregnancies occurring during the program as well as in a restricted cohort of MAR-exposed pregnancies to evaluate the impact of indication (infertility/subfertility) bias. MAR conception was associated with an increased prematurity risk (aOR 1.46, 95%CI 1.25-1.72). All MAR types were associated with increased prematurity risk when compared to spontaneous conception: OS alone (aOR 1.47, 95%CI 1.04-2.07), ART alone (aOR 1.76, 95%CI 1.01-3.06), and OS/ART combined (aOR 1.43, 95%CI 1.19-1.73). Lastly, in Study 3, we aimed to quantify the risk of being born small/very small for gestational age (SGA, VSGA) associated with MAR overall and by subtype. In this study, knowing the MAR/prematurity association, we assessed the role of prematurity as an effect modifier in the association between MAR and SGA/VSGA. While no association was observed between MAR and SGA/VSGA, MAR was associated with an increased SGA risk (aOR 1.69, 95%CI 1.08-2.66) among preterms. Our findings show a significant increase of multiplicity during the program years, well above the thresholds targeted by the program administrators. OS alone particularly increases multiplicity the most, an MAR technique that cannot be controlled through single embryo transfer. MARs increase the risk of preterm, particularly among singleton pregnancies. Our results further confirm that they also increase the risk of SGA, specifically among preterm singleton pregnancies.

中國13億人口的內需市場已為各產業的新興目標，尤其是在醫藥產業，中國政府於2009年宣布將投注8,500億人民幣改革中國整體醫藥建設，更為目前身處於台灣飽和市場的本土藥廠的發展契機，加上兩岸近期簽署的兩岸經濟合作架構協議(ECFA)，未來兩岸商業互動將更為頻繁。台商藥廠如何在這各界搶占的中國市場占有一席之地？掌握通路即掌握市場。 影響通路建構的因素分析，是企業市場營銷的首要步驟，公司對影響通路建構的因素越是瞭解，越是能掌握變動的市場，做出調整以因應環境的變化。本研究首先從中國醫藥品生產企業發展概況的分析，引導出跨國藥廠(歐美等國與台灣企業)進入中國市場常見的問題，並研究影響其通路建構須掌握的三大分析構面，包括醫療體制、藥品管理相關法令，以及流通企業等。 在醫療體制部分，中國的醫療市場主要集中在國有醫院(public hospitals)，但國有醫院的營銷環境複雜，受到許多來自政策、地方主義、關係資本等因素的影響，使得外來投資企業在經營中國國有醫院市場上，皆需要各方面相當的營銷資源才足以支撐。 在藥品相關法令部分，中國政府為了整頓醫藥市場混亂的景象以及減輕民眾的用藥負擔，於1998年起陸續頒布了許多藥品管理相關法令，包括國家基本藥品目錄、藥品價格管理制度，以及藥品集中招標採購制度等，這些法令雖然規範與體制化了中國醫藥市場，但也約束了醫藥通路終端市場的藥品採購，並使藥廠的通路建構彈性大幅受限。另外，雖然過去由於中國專利法發展遲滯，致使許多歐美企業無法在中國發揮藥品發明專利之市場壟斷的作用，但中國於2007年再次修定並頒布新實施的藥品註冊管理辦法，已將中國的藥品專利保護之法律與行政制度進行初步連結，未來兩者整合性的發展，將塑造出更有利於擁有強大技術與專利能量的藥廠生存的環境，此為台商不可忽視的重要課題。 在流通企業部分，中國流通企業不僅了解當地行規，通常又擅長多角化經營，掌握了大多的終端客戶，往往能夠提供藥廠代銷、物流、倉儲、收款等服務，故在流通企業在中國醫藥通路上扮演著不可或缺的角色，藥廠對流通企業的通路功能依賴性極大。 台商過去進入中國醫藥市場發展十幾年來的商業模式，是否還能足以因應未來更變化多端的市場環境？而後進中國市場的台灣藥廠又該採取怎樣的進軍策略？面對未來，台商更應「衡外情、量已力」，從各面向深入瞭解影響中國醫藥品通路建構的因素，除了鞏固既有醫藥市場與通路資源外，更應積極思考如何提高通路系統的附加價值，開創嶄新的獲利模式。本研究後續將針對前述三大影響因素，分章論述分析，最後歸納與整理影響因素對台灣藥廠所造成的困難，並提具因應上的建議，期能提供在中國發展醫藥品市場的台商企業作為未來發展策略的參考依據。 / China’s great market demand has become the new target for international enterprises, especially in pharmaceutical industry. China government announced the investment of 850 billion RMB to ameliorate the medical infrastructure in China, which indicates an opportunity for Taiwan pharmaceutical companies. The Economic Cooperation Framework Agreement (ECFA) between Taiwan and China will encourage a more enthusiastic interaction across the strait. Channel strategy will be the key to predominate the highly competent China market for Taiwan pharmaceutical companies. Analysis on channel construction will be the first step for industrial marketing strategy. The better a company understands the factors influential for channel construction, the better it can get control in the ever-changing market and adjust itself to cope with any alteration in the environment. This thesis will begin with an introduction on the development of pharmaceutical industry in China and thus induce some common issues with which international pharmaceutical companies are confronted in China market. It will analyze the channel construction from three important perspectives, healthcare system, pharmaceutical regulations, and logistics industry. Public hospitals play a major role in the healthcare system of China market. The marketing in public hospital involves complicated variables, including policy, local protectionism, and relationship capital. Non-local companies need every considerable resource to manage the marketing in public hospitals. In order to reform the healthcare market and lower the medical expense, China government announced several pharmaceutical regulations, including National Reimbursement Drug List (NRDL), Medicine pricing policy, and Pharmaceutical Centralized Public Bidding Procurement process. On one hand, these regulations help to put the market into order; on the other hand, it sets restricts on the retail sales and the channeling flexibility of the pharmaceutical company. Due to the slow development of China patent law in the past, moreover, a lot of American or European pharmaceutical companies could not develop an exclusive market for their drug through patent system. New Provisions for Drug Registration revised and announced by China government in 2007 established an initial connection between legal and administrative system of drug patent protection. Such integrated development will form an environment more suitable for pharmaceutical companies which possess powerful technology and patents, a significant trend for Taiwan companies’ attentions. China logistics companies understand local law and regulation and are usually familiar with multi-business strategy. They control most of the retailers and can offer sales agency, logistics, storage, and agency receipt. Logistic industry plays an important role in China pharmaceutical channel and is indispensable to pharmaceutical companies. It will be questionable whether Taiwan companies’ old business model can be sufficient for the changing China pharmaceutical market in the future. The newcomers should ponder more on their strategy for the market as well. Taiwan companies need to take the external condition and their own strength into consideration, understanding every factor of China pharmaceutical channel construction. Besides strengthening the original market and channels, Taiwan companies should aggressively enhance the add-value of channel system and find out new profit model. This thesis will focus on and elaborate the three perspectives and analyze the difficulties they bring upon Taiwan pharmaceutical companies, proposing possible solutions and future strategy for those who aim to develop their pharmaceutical business in China.

<p>Uvod: Vi&scaron;eplodne trudnoće se javljaju u 1,5% svih trudnoća nakon spontane koncepcije, dok nakon postupaka vantelesne oplodnje ovaj postotak u Evropi iznosi preko 20% uz velike varijacije među zemljama. U na&scaron;oj sredini, stopa vi&scaron;eplodnih trudnoća nakon postupaka vantelesne oplodnje iznosi daleko iznad 30%. Pojava hipertenzivnog sindroma u trudnoći, gestacijskog dijabetesa, operativnog zavr&scaron;avanja trudnoće, prevremenog porođaja, male porođajne telesne mase, neurolo&scaron;kih sekvela kod rođene dece i gotovo svih drugih komplikacija po majku i plod, kao i celokupno opterećenje zdravstvenog sistema vi&scaron;estruko su veći kod vi&scaron;eplodnih u odnosu na jednoplodne trudnoće i udeo navednih komplikacija raste sa brojem plodova. Sa druge strane deca iz postupaka vantelesne oplodnje čine i do 4,5% sve živorođene dece u pojedinim zemljama, &scaron;to uz činjenicu da infertilitet pogađa 16-18% parova u na&scaron;oj sredini daje ovoj pojavi posebnu dimenziju i činije i dru&scaron;tvenim problemom. Perinatalni ishodi trudnoća iz postupaka vantelesne oplodnje su u velikoj meri kompromitovani visokom stopom multiplih trudnoća, koje se danas smatraju komplikacijom, a ne uspehom postupaka vantelesne oplodnje. Jednoplodne trudnoće iz postupaka vantelesne oplodnje u većim studijama pokazuju diskretno slabije perinatalne ishode u odnosu na one spontano začete, dok kod vi&scaron;eplodnih trudnoća ova korelacija nije jasno izražena i dokumentovana, uz prisutnu dilemu da li je vi&scaron;eplodnost sama po sebi ili način koncepcije glavni problem u zapaženoj pojavi. Cilj rada: Uporediti perinatalne ishode vi&scaron;eplodnih trudnoća nastalih postupcima vantelesne oplodnje i spontano začetih kao i perinatalne ishode jednoplodnih i vi&scaron;eplodnih trudnoća iz postupaka vantelesne oplodnje. Pored navdenog cilj rada je i ukazati sveobuhvatnost navedenog problema i na moguća re&scaron;enja za smanjenje njihove učestalosti. Materijal i metode: Kombinacijom retrospektivne opservacione studije i prospektivne longitudinalne kohortne studije u periodu analizom perinatalnih ishoda pacijentkinja porođenih na Klinici za ginekologiju i aku&scaron;erstvo Kliničkog centra Vojvodine u periodu od od 01.01.2008. do 31.12.2010. godine, studija je analizirala i poredila perinatalne ishode kod 174 spontano začete vi&scaron;eplodne trudnoće, 163 vi&scaron;eplodne trudnoće nastale postupkom vantelesne oplodnje, kao i 155 jednoplodnih trudnoća začete postupkom vantelesne oplodnje. Analizirani parametric bili su telesna masa novorođenčeta, dostignuta gestacijska starost, vrednosti Apgar skora, učestalost hipertenzivnog sindroma kod majke i brojni drugi parametri perinatalnog ishoda. Uzeti od strane obučenih kliničara i uno&scaron;eni u posebno dizajniranu bazu podataka, rezultati su statistički analizirani u program JMP ver 9.0 (SAS publisher) uz kori&scaron;ćenje ANOVA analize za testiranje statističke značajnosti između srednjih vrednosti kontinuiranih varijabli, dok je statistička značajnost razlike učestalosti kategorijskih varijabli je određivana Pearsonovim &chi;2 testom. Rezultati: Jednoplodne ART trudnoće uz prosečnu starost od 33,5 godine, prosečnu gestacijsku starost na porođaju od 38,26 gn, udeo prevremenih porođaja od 12,9%, prosečnu telesnu masu od 3258 g, AS u prvom minutu od 8,35 i u petom minutu od 9,2, stopu carskog reza od 65,81%, udeo GDM-a od 7,1%, anemije od 41,94% i preeklampsije od 4,52%, ima sve relevantne parametre perinatalnog ishoda statistički značajno (p&lt;0.0001) superiornije od kako ART tako i non ART blizanačkih trudnoća. ART blizanačke trudnoće pokazale su prosečnu starost majke od 32,9 godina, prosečnu gestacijsku starost na porođaju od 35,6 gn, udeo prevremenih porođaja od 58,27%, prosečnu telesnu masu od 2374 g, AS u prvom minutu od 7,45 i u petom minutu od 8,65, stopu carskog reza od 83,7%, udeo GDM-a od 15,11%, anemije od 78,42% i preeklampsije od 12,23%, dok su non ART blizanačke trudnoće pokazale prosečnu starost majke od 28,8 godina, prosečnu gestacijsku starost na porođaju od 36,08 gn, udeo prevremenih porođaja od 49,71%, prosečnu telesnu masu od 2433 g, AS u prvom minutu od 7,75 i u petom minutu od 8,75, stopu carskog reza od 58,33%, udeo GDM-a od 7,02%, anemije od 67,84% i preeklampsije od 11,11%. Pored godina majke i udela carskog reza koji su bili vi&scaron;i u ART blizanačkim trudnoćama (&lt;0.0001), kao i blago veće pojavi poremećaja količine plodove vode (p=0,033), gotovo svi ostali pokazatelji toka i ishoda trudnoće bili su komparabilni u navedenim grupama. Diskusija i zaključak: Studija je pokazala da su tok i ishod vi&scaron;eplodnih trudnoća nastalih spontano i postupcima vantelesne oplodnje ekvivalentni u gotovo svim pokazateljima uz sličnu prosečnu telesnu masu i gestacijsku starost novorođenčadi, kao i da su svi navedeni parametri ovih vi&scaron;eplodnih trudnoća bez obzira na način koncepcije upadljivo i podjednako lo&scaron;iji u poređenju sa jednoplodnim trudnoćama iz postupka vantelesne oplodnje. Izuzimajući vi&scaron;eplodnost kao factor rizika deca iz postupaka vantelesne oplodnje su generalno zdrava. Sama vi&scaron;eplodnost, a ne način koncepcije predstavljaju problem, koje se sa pravom smatra najvećom komplikacijom vantelesne oplodnje. Dodatna analiza iskustava drugih zdravstvenih sistema ukazuje da jedino &scaron;iroka i sveobuhvatna implementacija strategije vraćanja samo jednog embriona (Single embryo transfer &ndash; SET) može da dovede do smanjivanje stope multiplih trudnoća nakon postupaka vantelesne oplodnje, i sledstvenih komplikacija, a bez ugrožavanja samog uspeha vantelesne oplodnje. Iskustva drugih zdravstvenih sistema ukazuju da je uspe&scaron;na implementacija SET-a jedino moguća uz angažovanje celog dru&scaron;tva, zajedno sa brojnim legislativnim merama iz domena nadzora, kontrole i finansiranja postupaka vantelesne oplodnje. Obim i način finansiranja postupaka vantelesne oplodnje od strane države (uz vi&scaron;e besplatnih poku&scaron;aja za infertilne parove) uz obaveznu upotrebu SET-a, i sistema krioprezervacije na osnovu primera iz prakse predstavlja ključ u borbi za smanjenje problema vi&scaron;eplodnih trudnoća nakon postupaka vantelesne oplodnje.</p> / <p>Introduction: Multiple pregnancies occur in 1.5% of all pregnancies after spontaneous conception and in more than 20 % of all pregnancies concieved after assisted reproductive technologies in Europe, with large variations between countries. In our setting, the rate of multiple pregnancies after the ART is well above 30%. The occurrence of hypertensive syndrome in pregnancy, gestational diabetes, operative delivery, premature birth, low birth weight, neurological and developmental impairment in children, and almost all the other complications for the mother and fetus, as well as the entire burden of the health system are several times higher in multiple pregnancies compared with singleton pregnancies. Incidence of&nbsp; forementioned complications rises with number of fetuses. On the other hand, children from in vitro fertilization procedures make up 4.5% of all live births in some countries, which together with the fact that infertility affects aproximately 16-18% of couples in our country gives an extra dimension to this phenomenon and makes it not just medical but wider social problem. Perinatal outcomes of pregnancies after assisted reproductive technologies (ART) are greatly compromised by the high rate of multiple pregnancies, which are now considered to be a complication rather than success of ART procedures. ART Singleton pregnancies have, in larger studies, show discretely lower perinatal outcomes compared with those conceived spontaneously, while for the multiple pregnancies, this correlation is not clearly expressed and documented. There remains dilemma whether multiplicity itself or the way of conception (ART vs. non ART) constitutes a major problem in the observed differences regarding perinatal outcome of ART pregnancies. Objective: To compare the perinatal outcomes of multiple pregnancies conceived by In vitro fertilization (IVF) and spontaneously and perinatal outcomes of IVF conceived singleton and multiple pregnancies. Additional aim of this thesis is to point out the complexity of this problem and offer possible solutions. Materials and Methods: Design of a study was a combination of retrospective and prospective observational longitudinal cohort study. Analysis included pregnancies which had delivery at the Department of Gynecology and Obstetrics, Clinical Center of Vojvodina in the period from 1.01.2008. to 31.12.2010. The study analyzed and compared the perinatal outcomes in 174 spontaneous conceived multiple pregnancies, 163 multiple pregnancies resulting from IVF procedures, and 155 singleton pregnancies conceived by IVF procedure. Analyzed parameters were newborns birth weight, gestational age at delivery, the value of the Apgar score, occurrence of hypertensive syndrome in pregnancy, gestational diabetes, as well as numerous parameters of perinatal outcome. Taken by trained clinicians and were entered into a specially designed database, the results were statistically analyzed in JMP ver 9.0 software (SAS publisher) using ANOVA analysis to test the statistical significance between the mean values of continuous variables, while the statistical significance of the difference in frequency of categorical variables was assessed by Pearsons &chi;2 test. Results: ART singleton pregnancies had an average mothers age of 33.5 years, the average gestational age at birth of 38.26 gestational weeks (gw), preterm delivery rate of 12.9%, average birth weight 3258 g, Apgar score (AS) in the first minute 8.35, and in the fifth minute 9.2, cesarean section rate 65.81%, Gestational diabetes (GDM) in 7.1% pregnancies, anemia occurred in 41.94% of pregnancies, while preeclampsia was observed in 4.52% of all pregnancies. All relevant parameters of perinatal outcome were significantly (p&lt;0.0001) superior to both ART and non-ART twin pregnancies. ART twin pregnancy showed the average mothers age of 32.9 years, the average gestational age at birth of 35.6 gw, the preterm delivery rate 58.27%, the average body weight newborns 2374 g, AS in the first minute of 7.45, and in the fifth minute of 8.65, the cesarean section rate of 83.7%, GDM in 15.11% of all pregnancies, anemia occurred in 78.42% and preeclampsia in 12.23% of pregnancies, while the non-ART twin pregnancy showed an average mothers age of 28.8 years, the average gestational age at birth of 36.08 gw, the preterm delivery rate of 49.71%, the average body weight of 2433 g, AS in the first minute of 7.75 in the fifth minute 8.75, the caesarian section rate of 58.33%, GDM-a occurred in 7.02%, anemia in 67.84% and preeclampsia in 11.11% of pregnancies. Except for maternal age and the caesarean section rate, which were significantly higher in ART twin pregnancies (p&lt;0.0001), as well as small increase in proportion of amniotic fluid volume disorders (p = 0.033), almost all other parameters of perinatal outcome of were comparable in these groups. Discussion and Conclusion: The study showed that the course and outcome of multiple pregnancies conceived spontaneous and after IVF procedures are equivalent in almost all parameters with similar average body weight and gestational age at birth, and that all these parameters of multiple pregnancies regardless of the conception mode are equally worse compared with singleton pregnancies from IVF procedures. With the exception of multiplicity as a risk factor children from in vitro fertilization procedures are generally healthy. Multiplicity itself and not the mode of conception presented a problem, which is rightly considered the major complication of IVF today. Additional analysis of the experiences of other health system indicates that only a broad and comprehensive implementation of strategy to return only one embryo (SET&ndash;single embryo transfer) can lead to a reduction of the rate of multiple pregnancies after IVF procedures, and the accompanying complications, without compromising IVF success. The experience of other health systems indicate that a successful implementation of SET is only possible with the involvement of the whole society, along with a number of legislative measures in the field of monitoring, control and reimbursement of assisted reproduction procedures. The scope and funding of an IVF procedures (with more free attempts for infertile couples, reimbursed by public health) with mandatory use of SET, and good cryopreservation programs are, based on examples in other countries who had successfully dealt with his problem, is the key in reducing the problem of multiple pregnancies after IVF procedures.</p>

Advances in medical technology have altered the need for certain types of surgery to be performed in traditional inpatient hospital settings. Less invasive surgical procedures allow a growing number of medical treatments to take place on an outpatient basis. Hospitals face growing competition from ambulatory surgery centers (ASCs). The competitive threats posed by ASCs are important, given that inpatient surgery has been the cornerstone of hospital services for over a century. Additional research is needed to understand how surgical volume shifts between and within acute care general hospitals (ACGHs) and ASCs. This study investigates how medical technology within the hospital industry is changing medical services delivery. The main purposes of this study are to (1) test Clayton M. Christensen’s theory of disruptive innovation in health care, and (2) examine the effects of disruptive innovation on appendectomy, cholecystectomy, and bariatric surgery (ACBS) utilization. Disruptive innovation theory contends that advanced technology combined with innovative business models—located outside of traditional product markets or delivery systems—will produce simplified, quality products and services at lower costs with broader accessibility. Consequently, new markets will emerge, and conventional industry leaders will experience a loss of market share to “non-traditional” new entrants into the marketplace. The underlying assumption of this work is that ASCs (innovative business models) have adopted laparoscopy (innovative technology) and their unification has initiated disruptive innovation within the hospital industry. The disruptive effects have spawned shifts in surgical volumes from open to laparoscopic procedures, from inpatient to ambulatory settings, and from hospitals to ASCs. The research hypothesizes that: (1) there will be larger increases in the percentage of laparoscopic ACBS performed than open ACBS procedures; (2) ambulatory ACBS will experience larger percent increases than inpatient ACBS procedures; and (3) ASCs will experience larger percent increases than ACGHs. The study tracks the utilization of open, laparoscopic, inpatient and ambulatory ACBS. The research questions that guide the inquiry are: 1. How has ACBS utilization changed over this time? 2. Do ACGHs and ASCs differ in the utilization of ACBS? 3. How do states differ in the utilization of ACBS? 4. Do study findings support disruptive innovation theory in the hospital industry? The quantitative study employs a panel design using hospital discharge data from 2004 and 2009. The unit of analysis is the facility. The sampling frame is comprised of ACGHs and ASCs in Florida and Wisconsin. The study employs exploratory and confirmatory data analysis. This work finds that disruptive innovation theory is an effective model for assessing the hospital industry. The model provides a useful framework for analyzing the interplay between ACGHs and ASCs. While study findings did not support the stated hypotheses, the impact of government interventions into the competitive marketplace supports the claims of disruptive innovation theory. Regulations that intervened in the hospital industry facilitated interactions between ASCs and ACGHs, reducing the number of ASCs performing ACBS and altering the trajectory of ACBS volume by shifting surgeries from ASCs to ACGHs.